G
Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction.
Investor insights
Funding rounds participated in
$76M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2016
Funding rounds raised
Total raised
$76M
from 1 investors over 1 rounds
G
Generation Bio raised $76M on April 23, 2023
Investors: Moderna